AndhraNews.net
Home » Features » Health » Colorectal cancer

Colorectal cancer


About Colorectal cancer

Colorectal cancer in Japan

The prevalence of colorectal cancer is increasing rapidly in Japan. The number of cancer deaths due to colorectal cancer has already exceeded gastric cancer. It is the most frequent cause of death in the female population. If we can detect cancers or pre-cancerous lesions at an early stage, cancer deaths can be prevented by performing endoscopic resection," said Dr. Yamamoto. "We have a special need for cost-effective preventive medicine technologies such as the Third Eye Retroscope. I look forward to becoming involved with the scientific and clinical aspects of this device, and hope one day to be able to offer it to my patients in Japan.

Recent Colorectal cancer research and findings

In September 09, Amgen announced detailed results from the Phase 3 '203' trial evaluating Vectibix (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the first-line treatment of metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved median progression-free survival (PFS) by 1.6 months (9.6 versus 8.0 months for patients treated with FOLFOX alone, (hazard ratio 0.80; p=0.02)) in patients with KRAS wild-type mCRC (primary endpoint). The results were presented at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 10LBA).

Colorectal cancer in News

Study Analyzes Cost of Automated Cancer Screening Outreach Using TopCare at Massachusetts General Hospital

SpectraScience Study Confirms Accuracy of WavSTAT4 in the Diagnosis of Small Colorectal Cancer Polyps
SAN DIEGO, CA--(Marketwired - December 08, 2015) - SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that in a presentation at United European Gastroenterology Week (UEGW) by Dr

Funk Out Cancer and Widen Raise Over $53,000 for Cancer Research
MADISON, WI--(Marketwired - December 04, 2015) - Widen Enterprises, makers of digital asset management software (DAM), announced that the company has helped Funk Out Cancer raise $53,023 to fund research in Dr. Dustin Deming's lab at the University of Wisconsin Paul C. Carbone Cancer Center

Molecular Diagnostics Market Worth $9.50 Billion by 2022: Grand View Research, Inc.
The global molecular diagnostics market is expected to reach over USD 9.50 billion by 2022, according to a new report by Grand View Research Inc. Growing prevalence of chronic diseases and infections such as HPV and influenza is anticipated to be the key driver for molecular diagnostics market growth

Epigenetics Market Worth $16.31 Billion by 2022: Grand View Research, Inc.
The global epigenetics market is expected to reach USD 16.31 billion by 2022, according to a new report by Grand View Research, Inc. Growing worldwide prevalence of cancer and other diseases with epigenetic modification base is expected to drive market growth during the forecast period.

MD Anderson's Moon Shots Mission Grows to Confront Six More Cancer Types
HOUSTON, TX--(Marketwired - October 30, 2015) - MD Anderson's Moon Shots Program, an unprecedented effort and novel organizational model designed to more rapidly convert scientific discoveries into life-saving advances, has expanded its targets, adding several of the most intractable cancers to its campaign.

ARMO BioSciences Presents Positive Phase 1 Trial Results of AM0010 at Upcoming Medical Conferences
ARMO BioSciences, Inc., a leading developer of immuno-oncology therapeutics, today announced that positive results from an ongoing Phase 1 clinical trial of ARMO's investigational drug AM0010 (PEGylated Interleukin-10) for the treatment of advanced solid tumors, will be presented at three upcoming oncology conferences. The conferences are:

EDP Biotech Achieves ISO 13485 Certification
EDP Biotech, a privately-held company providing in-vitro diagnostic test kits for the detection of colorectal cancer, has achieved ISO 13485 and Canadian Medical Device Regulations Certification

Genomic Classifier Appears to Predict Metastasis in Prostate Cancer Patients Following Prostatectomy

A Shorter Radiation Therapy Schedule Can Be as Effective as a Conventional Schedule for Men With Low-Risk Prostate Cancer

Hypofractionated Radiation Therapy May Be an Acceptable Treatment for Some Patients With Localized Prostate Cancer

Androgen Deprivation Therapy for Two Years After Radiation Therapy Improves Disease-Free Survival in Patients With Advanced Prostate Cancer

Anti-Androgen Therapy and Salvage RT Improves Overall Survival for a Prostate Cancer Recurrence After a Prostatectomy

Patients With Intermediate-Risk Meningiomas Who Receive Postoperative Radiation Therapy Have Excellent Three-Year Progression-Free Survival
SAN ANTONIO, TX--(Marketwired - October 20, 2015) - Patients with intermediate meningiomas treated with radiation therapy (RT) after surgery experienced a 96 percent three-year progression-free survival rate and had minimal adverse events, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 57th Annual Meeting.

Use of Involved Field Irradiation Therapy for Locally Advanced Esophageal Cancer Reduces Toxicity

Pediatric Patients With Ependymoma Have Favorable Outcomes With Immediate Post-Surgical Radiation Therapy

Advanced Cancer Patients Have Better Quality of Life When Radiation Therapy and Palliative Care Are Coordinated, Based on Patient-Reported Feedback

Frequent Post-Treatment Follow-Up by Advance Practice Nurses Improves Care for High-Risk Head and Neck Cancer Patients

Cancer Patients With Bone Metastases Undergoing Radiation Therapy for Symptom Control Have a Lower Rate of Pain Flare With Steroid Use
SAN ANTONIO, TX--(Marketwired - October 19, 2015) - The steroid dexamethasone reduces radiation-induced pain flare in cancer patients with painful bone metastases, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 57th Annual Meeting.

New Survey Showed GI Health and Anti-Aging Benefits of Morinaga's Probiotics Milk with BB536
Business Wire IndiaMorinaga Milk Industry Co., Ltd

IsoRay's Cesium-131 Used in World's First Veterinary Implant in a Horse With Cancer
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced the world's first veterinary implant of a horse suffering from cancer utilizing IsoRay's Cesium-131 internal radiation (brachytherapy) cancer therapy.

NCCN Launches 3D Virtual Simulator Learning Platform
FORT WASHINGTON, PA--(Marketwired - December 04, 2014) - The National Comprehensive Cancer Network® (NCCN®) has launched a 3D Virtual Metastatic Colorectal Cancer (mCRC) Simulator Learning Platform as part of the NCCN Continuing Education Program. To develop the 3D Virtual mCRC Simulator Learning platform, NCCN collaborated with Syandus, Inc

Alchemia Announces Departure of Chief Executive Officer
Alchemia Limited, (ASX: ACL) a drug discovery and development company, today announced the departure of Thomas Liquard as Chief Executive Officer.

Alchemia Announces Phase III Trial Results for HA-Irinotecan in Metastatic Colorectal Cancer
Alchemia Limited (ASX: ACL)

CEO Kevin T. Conroy of Exact Sciences to Be Interviewed Live on Clear Channel -- iHeart Business Talk Radio -- October 16, 2014
"The Traders Network Show" broadcasted daily on Clear Channel -- iHeart Radio DFW1190AM KFXR, is pleased to announce Exact Sciences (NASDAQ: EXAS) CEO Kevin T. Conroy will be interviewed live on Thursday, Oct 16th, at 7:30am EDT by host Michael Yorba streamed globally on iHeart Radio

Looking Back: 20 Years of Colorectal Cancer Treatment Breakthroughs Improve Survival, Advance Evidence-Based Choices
FORT WASHINGTON, PA--(Marketwired - October 09, 2014) - The National Comprehensive Cancer Network® (NCCN®) has published the 20th annual editions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon and Rectal Cancers, two of the eight original NCCN Guidelines® published in November 1996. 

Alchemia Announces Database Lock of Its HA-Irinotecan Pivotal Phase III Trial in Metastatic Colorectal Cancer
Alchemia Limited (ASX: ACL)

immixGroup Foundation Tenth Annual Charity Golf Tournament Raises $125,000 for Cancer Research
MCLEAN, VA--(Marketwired - October 03, 2014) - The immixGroup Foundation announced today it has raised $125,000 to support cancer research, education, and patient care at Johns Hopkins. The foundation is a non-profit 501(c)(3) organization affiliated with immixGroup, Inc. immixGroup helps technology companies do business with the government.

SpectraScience Brings on SenaHill as Advisor
SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announces that it has engaged SenaHill Advisors, LLC ("SenaHill") as its advisor in connection with a proposed equity financing of up to $40 million and review of strategic alternatives. SenaHill offers brokerage services through its affiliate, Parker Rose LLC

Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014
AACHEN, GERMANY--(Marketwired - October 01, 2014) -

Vela Diagnostics Launches First CE-IVD Next-Generation Sequencing Oncology Panel for Melanoma Testing on the Automated Sentosa(R) NGS Workflow
Vela Diagnostics announced today the CE-IVD launch of the Sentosa® SQ Melanoma Panel for Next-Generation Sequencing (NGS)-based gene sequence variant detection and identification.

Renowned USC/Norris Cancer Researcher, Dr. Heinz-Josef Lenz, Joins Panther Biotechnology Board of Directors
Panther Biotechnology, Inc. (OTC Pink: PBYA) (PINKSHEETS: PBYA) announced today that Heinz-Josef Lenz, M.D., F.A.C.P., associate director of clinical research at USC/Norris Comprehensive Cancer Center and co-chair of the Southwest Oncology Group's Gastrointestinal Committee, has been appointed to Panther Biotechnology's Board of Directors.

IsoRay's Cesium-131 Cancer Treatment Products and Methods to Be Featured in Oral Presentations by Industry Leaders During the American Society for Radiation Oncology Convention (ASTRO)
IsoRay Inc. (NYSE MKT: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO)

Dako Sponsors European Pathology Congress for Second Straight Year
GLOSTRUP, Denmark, August 29, 2014.

Alchemia Appoints Jenni Pilcher as Chief Financial Officer
Alchemia Limited (ASX: ACL), a drug discovery and development company, announced today the appointment of Ms. Jenni Pilcher as its Chief Financial Officer (CFO). Ms. Pilcher brings extensive financial leadership experience to Alchemia. She is currently the CFO of Mesoblast, where she has been part of the executive team for the past seven years, and she also serves as Company Secretary

Biomerica to Supply Its Colorectal Screening Point of Care Test to Multinational Pharmaceutical Company With Over $40 Billion in Sales
Biomerica, Inc. (OTCBB: BMRA) announced today it will supply its EZ Detect colorectal screening test to a multinational pharmaceutical company that has over $40 billion in revenues and over 70,000 employees worldwide

IsoRay's Cesium-131 Isotope Produces Excellent Results in Treating Metastatic Brain Cancer as Published in the Journal of Neurosurgery
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the publication of the first major peer reviewed study showing superior results using IsoRay's Cesium-131 seeds in the treatment of metastatic brain cancer.

Boehringer Ingelheim initiates global Phase III study investigating nintedanib* in patients with colorectal cancer refractory to standard treatments
For Ex-US and Ex-UK Media Only

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy
For Ex-US and Ex-UK Media Only

GlaxoSmithKline Pharmaceuticals Announces Q2 Results
The core Pharmaceuticals business grew by 3.7 % for the quarter. The quarter continued to see the impact of the base effect of differential pricing cuts due to the Price Control Order, extending coverage to the National List of Essential Medicines (NLEM).   Commenting on the performance, Dr. Hasit B

Bavarian Nordic - Interim Financial Report for the Period 1 January to 30 September 2013
KVISTGAARD, Denmark, November 14, 2013 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first nine months of 2013. Revenue for the period was DKK 875 million (2012: DKK 750 million) and the result before tax was a loss of DKK 18 million (2012: DKK 17 million profit)

Medical Cannabis Financial Group, Inc. Announces Merger Transaction With Refill Energy, Inc.
Refill Energy, Inc. (PINKSHEETS: REFG), a Nevada Corporation (the "Company") announces the merger between Refill Energy, Inc. and Medical Cannabis Financial Group. Refill Energy, Inc. completed a reorganization with Medical Cannabis Financial Group, Inc., which is a software solutions company focused on solutions for the Medical Marijuana industry

VolitionRx Announces Engagement of MissionIR Investor Relations Services
VolitionRx Ltd. (OTCQB: VNRX) (the "Company") today announces that it has engaged the investor relations services of MissionIR. Through a network of investor-oriented sites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital as well as improve shareholder value.

Widen Helps Funk Out Cancer Raise Over $41,000 for Cancer Research
Widen Enterprises, makers of digital asset management software (DAM), announced that the company has helped Funk Out Cancer raise $41,296 for the University of Wisconsin Paul C. Carbone Cancer Center

e-MDs' Customer Jennifer Brull, MD, Is Only Physician in U.S. Named a Software Advice EHR All-Star in Two Categories
e-MDs, a leading provider of electronic health records (EHRs) and practice management (PM) solutions, announced today that Jennifer Brull, MD, FAAFP, a solo family physician in Kansas and e-MDs customer since 2007, is the only physician to be recognized in two separate categories in Software Advice's 2013 EHR All-Stars.

Affimed Therapeutics Appoints Dr. Jens-Peter Marschner as Chief Medical Officer
Affimed Therapeutics AG /Affimed Therapeutics Appoints Dr. Jens-Peter Marschner as Chief Medical Officer. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

MissionIR Releases Exclusive Audio Interview With CytRx Management
MissionIR today announces the online availability of its interview with CytRx Corp. (NASDAQ: CYTR) President and Chief Executive Officer Steven Kriegsman, as well as the company's Vice President of Business Development and Investor Relations David Haen. The full audio interview is available at: http://cytr.missionir.com/interview.html.

Johns Hopkins and Rutgers Medical School Now Utilizing IsoRay's Cesium-131 Sutured Seeds in Treating Metastatic Brain Cancer
IsoRay Inc. (NYSE MKT: ISR) (NYSE Amex: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth October 21-24th at the Annual Meeting of the Congress of Neurological Surgeons

IsoRay's Cancer Fighting Cesium-131 Seeds, Sutures and Seeded Mesh Receive High Marks With Six Abstracts Presented During (ASTRO) the American Society for Radiation Oncology Conference
IsoRay Inc. (NYSE MKT: ISR) (NYSE Amex: ISR) (http://www.isoray

Widen Enterprises Presents Funk Out Cancer
Widen Enterprises, makers of digital asset management software (DAM), announced today that the company will be the presenting sponsor of Funk Out Cancer, a concert and silent auction that raises money for the UW Carbone Cancer Center. An annual event held in memory of Kate Gates Falaschi, Funk Out Cancer will take place on October 19, 2013, at Madison's Barrymore Theatre

Achieving Personal Harmony and Balance During Cancer
(Family Features) What if after surviving your first cancer diagnosis at the age of 51, you were re-diagnosed just 18 months later? Metastatic colorectal cancer patient Dave Johnson experienced that first-hand, and was initially reluctant and scared to tell his family, friends and co-workers.

Onyx Pharmaceuticals Announces Data Presentations at 2013 European Cancer Congress
Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced the upcoming presentations of data highlighting Nexavar® (sorafenib) tablets and Stivarga® (regorafenib) tablets at the 2013 European Cancer Congress (ECCO/ESMO/ESTRO), September 28 - October 1, 2013 in Amsterdam, Netherlands.

Bavarian Nordic Reports Financial Results for the First Half of 2013
KVISTGAARD, Denmark, August 22, 2013 - Bavarian Nordic A/S (OMX: BAVA) today publishes its results for the first half of 2013. Revenue for the period was DKK 556 million (2012: DKK 445 million) and the result before tax was a loss of DKK 43 million (2012: DKK 13 million loss)

Alchemia Reports Record Fondaparinux Quarterly Profit Share
A$3.9m profit share for quarter ending 30 June 2013 Total Alchemia fondaparinux profit share of A$9.6m for FY 2013 Fondaparinux approved in Canada with launch expected soon Australian drug discovery and development company Alchemia Limited (ASX: ACL) today announced a record quarterly profit share of A$3.9 million (US$3

IsoRay's Cesium-131 Cancer Treatment Products and Results Will Be Discussed in a Number of Papers Presented During the American Society for Radiation Oncology Convention (ASTRO)
IsoRay Inc. (NYSE MKT: ISR) (NYSE Amex: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the 55th Annual Meeting of the American Society for Radiation Oncology (ASTRO)

SpectraScience Announces Q2 2013 Revenue
SpectraScience, Inc. (OTCQB: SCIE), a San Diego-based medical device company, today announced it expects to recognize revenue of approximately $120,000 for its second quarter ending June 30, 2013.

Prima BioMed to Move Forward With Phase 2 Clinical Program for CVac(TM) in Pancreatic, Colorectal, and Triple-Negative Breast Cancers
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") today announced that it will move forward with three separate phase 2 clinical trials to evaluate the potential of CVac™ for the treatment of resectable pancreatic cancer, metastatic colorectal cancer, and triple-negative breast cancer

Quintiles Advances New Approach to Speed Biomarker-Targeted Therapies to Cancer Patients
Quintiles today announced plans to improve the development of biomarker-targeted therapies through a novel approach that promotes the genomic “pre-profiling” of cancer patients

Promises and Challenges of Personalized Cancer Medicine Addressed at WIN Symposium 2013
400 delegates from around the globe attended the fifth WIN Symposium, held in Paris, July 10-12. This year’s overarching theme was “Personalized Cancer Therapy: From Innovation to Implementation”

GE Healthcare Research Determines Bad Habits Add $33.9 Billion to Annual Global Cost of Cancer
GE Healthcare today released secondary research findings indicating that bad habits and lifestyle choices are contributing approximately $33.9 billion annually to the costs related to cancer. Furthermore, the same research revealed that by reducing bad habits, global healthcare systems could potentially save $25 billion each year.

Equity Brief: Ratings Changes for December 20th: SASR, SD, SGY, SLGN, SNSS, ST, STN, TAP
A number of stocks were upgraded and downgraded by equities research analysts today, as reported by Analyst Ratings Network (http://bit.ly/equitybriefdaily) and Equity Brief:

Near Term Catalyst Has ArQule Poised for a Move Up
ArQule, Inc. engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes.

ArQule (ARQL) Poised For A Quick Move Up On Near Term Catalyst
By Scott Matusow, Contributor@scottmatusow

A Strong Speculative BioPharma Poised For A Quick Move Up On Near Term Catalyst
By Scott Matusow, Contributor@scottmatusow

IsoRay's Cesium-131 Seeds Proves Successful for Brain Cancer Treatment as Presented by Weill Cornell and Barrow Neurological to The Society Of Neuro-Oncology
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the presentation of clinical findings at two medical centers of the successful treatment of brain cancers and tumors using IsoRay's patented Cesium-131 (Cs-131) sutured seeds and seed sutured mesh for internal radiation therapy.

Adherex Reports Positive Preliminary Interim Phase II Results for Eniluracil plus 5- Fluorouracil and Leucovorin at the CTRC-AACR San Antonio Breast Cancer Symposium
Patients who had rapid disease progression on capecitabine treatment(1) (N=9) and crossed over to take eniluracil/5-FU/leucovorin (EFL) experienced the following:

Propanc Issues Summary of Recent Achievements
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), a developmental stage healthcare company focused on new cancer treatments for patients with solid tumors, issued a summary of recent achievements that position the company for planned future growth in the next twelve months.

Given Imaging Reports Third Quarter 2012 Results
Given Imaging Ltd. (NASDAQ: GIVN) today announced financial results for the third quarter ended September 30, 2012.

TapImmune Chairman Provides Corporate Update Including Progress on Clinical Trial Program and Scientific Collaborations
TapImmune Inc. (OTCBB: TPIV) Chairman and CEO Glynn Wilson, Ph.D., is pleased to provide this corporate update to our shareholders and other interested parties:

Onyx Pharmaceuticals Reports Third Quarter 2012 Financial Results

PropThink: ArQule Reports 3Q Results as Investors Now Look to Tivantinib's HCC Indication
By Jake KingOncology-focused ArQule, Inc. (NASDAQ:ARQL) reported third quarter financial results on Thursday morning, noting that cash, equivalents, and marketable investts totaled $140M on Sept. 30, and that the company will likely end the year with close to $130M

PropThink: SGNT Generic Leucovorin Launches; SPPI Should Absorb The News Well
By David MoskowitzShares of Spectrum Pharmaceuticals (NASDAQ:SPPI) have been under pressure as investors await the supply of generic leucovorin to increase and compete with SPPI's branded cancer treatment, Fusilev

IsoRay's Brain and Lung Cancer Products Showcased at the American Society for Radiation Oncology (ASTRO) Convention
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the 54th Annual Meeting of the American Society for Radiation Oncology (ASTRO). The annual meeting will take place October 28-31, 2012 in Boston, Massachusetts at the Boston Convention and Exhibition Center

Mauna Kea Technologies Announces New Data Supporting Clinical Utility of Cellvizio(R)

Given Imaging Reports New Studies on PillCam(R) COLON 2 Presented at UEG Week
Given Imaging Ltd

Given Imaging Announces Over 80 Studies at ACG 2012 and UEG Week 2012

Manhattan Endoscopy Center, the Largest Ambulatory Endoscopy Center in the State of New York, Opens in Midtown Manhattan
Manhattan Endoscopy Center LLC (MEC) celebrates the opening of their state-of-the-art facility located in the heart of Manhattan. The team of physicians includes world-renowned GI experts, researchers, and thought-leaders who advocate for timely screening, diagnosis, and treatment to improve health outcomes and help save lives

BB Biotech reports strong third quarter results
BB BIOTECH AG /BB Biotech reports strong third quarter results. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

PropThink: ArQule Rising on SPA Agreement with FDA, Further Indications for tivantinib
By Jake KingShares of ArQule (NASDAQ:ARQL) are up 8% on news that the FDA has agreed to a Special Protocol Assessment for the company's planned Phase III tivantinib trial. ArQule is designing a study of its lead candidate as a second-line Hepatocellular Carcinoma (HCC) treatment

Taiho Pharmaceutical Unveils Data on Eight Novel Anticancer Compounds in Bid to Become a New Global Leader in Oncology
Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Masayuki Kobayashi), the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies

INNO-GENE, A WARSAW STOCK EXCHANGE LISTED COMPANY IS THE FIRST IN THE WORLD TO DEVELOP ACCURATE DNA TESTING FOR CANCER AND PLANS TO ENTER THE US MARKET.
PRESS RELEASE

Mauna Kea Technologies Announces the Publication of a Study Confirming the Value of the Cellvizio(R) System in Colorectal Cancer Follow-Up
Mauna Kea Technologies (EURONEXT PARIS: MKEA), the leader in the endomicroscopy market, announced today the publication of a new study on colorectal cancer in a leading medical journal, Gastrointestinal Endoscopy (GIE)

Novartis highlights advances for patients with breast cancer and hematological diseases with over 160 SABCS and ASH abstracts
Novartis International AG /Novartis highlights advances for patients with breast cancer and hematological diseases with over 160 SABCS and ASH abstracts . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Signature Diagnostics to Present at the 23rd Annual Piper Jaffray Health Care Conference
Signature Diagnostics /Signature Diagnostics to Present at the 23rd Annual Piper Jaffray Health CareConference. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement

Scott Hamilton and Dorothy Hamill Join Skating Champions and Grammy Award Winning Artists to Celebrate Cancer Survivorship for "Kaleidoscope on Ice" -- A Holiday Spectacular
Olympic champions Scott Hamilton & Dorothy Hamill will co-host this year's Kaleidoscope on Ice, a holiday spectacular and musical extravaganza conceived to represent the full spectrum of colors around cancer awareness and to empower those battling cancer to celebrate survivorship. Kaleidoscope on Ice will air nationally on FOX on Thanksgiving Day (Nov

Given Imaging Initiates Pivotal Trial for PillCam(R) COLON 2 in Japan
Given Imaging (NASDAQ: GIVN), a world leader in GI medical devices and pioneer of capsule endoscopy, today announced the initiation of a pivotal PillCam® COLON 2 study in Japan intended to support the Company's planned regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

Why an apple a day can keep the doctor away
Antioxidants found in apple peels may lead to new treatments and therapies for people suffering from bowel inflammation disorders, according to a new research.

High fibre cereals and whole grains reduce bowel cancer risk
London, November 11(ANI): Consuming high fibre cereals can reduce the risk of bowel cancer, a study has found.

Southampton Varsity's research proves aspirin reduces cancer rates in people with hereditary risk
Research has finally provided proof that taking a regular dose of aspirin reduces the long-term risk of cancer in people with a family history of the disease by around 60 per cent.

'Sleeping Beauty' helps discover genes behind colorectal cancer
Scientists have unlocked a list of genes involved in colorectal cancer, thanks to a jumping gene with the fairy tale name "Sleeping Beauty".

Comment on this story

Share